STOCK TITAN

GeoVax Labs, Inc. Warrants - GOVXW STOCK NEWS

Welcome to our dedicated page for GeoVax Labs Warrants news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs Warrants stock.

GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company specializing in developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers.

Utilizing novel proprietary platforms like the modified vaccinia ankara - virus-like particle (MVA-VLP) vaccine platform, GeoVax's pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and gene-directed therapy for head and neck cancers.

Additional research programs focus on preventive vaccines against infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, along with immunotherapies for various solid tumors.

Recent achievements include positive initial safety and immune response findings from a Phase 2 clinical trial evaluating GEO-CM04S1, the COVID-19 vaccine, as a heterologous booster in 63 healthy adults who previously received the Pfizer or Moderna mRNA vaccine. The trial has demonstrated statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants.

Rhea-AI Summary

GeoVax Labs, a biotechnology firm focused on human immunotherapies and vaccines, announced participation in the Alliance Global Partners’ Virtual Healthcare Symposium on June 17, 2021. The management team will conduct 1-on-1 investor meetings during the event. GeoVax's development programs target vaccines for COVID-19, Zika, Ebola, HIV, and various cancers, utilizing an innovative MVA-VLP platform that stimulates robust immune responses akin to natural infections. For meeting requests, contact AGP Events at agpevents@allianceg.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Rhea-AI Summary

GeoVax Labs (Nasdaq: GOVX) will present at the 2021 BIO Digital event on June 10, focusing on its COVID-19 vaccine and cancer immunotherapy programs. CEO David Dodd will provide insights into the company's research and development efforts. A panel discussion titled, “Vaccine Business – Five Minutes of Fame or Five-Time Oscar Winner?” will take place on June 15 at 11:05am ET, featuring Dodd. GeoVax’s vaccine platform is centered on combating infectious diseases and cancers, utilizing a Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

GeoVax Labs, Inc. (GOVX) reported significant updates in their Q1 2021 financial results, including a net loss of $1.56 million, a 163% increase from Q1 2020. Cash reserves improved to $20.8 million, bolstered by a $10.3 million stock offering and $3.2 million from warrant exercises. The company is advancing its COVID-19 vaccine, supported by a $3.2 million NIH grant, focusing on a universal vaccine to counter multiple variants. GeoVax's patent portfolio expanded to over 70 applications, enhancing its position in COVID-19 and cancer immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

GeoVax Labs, Inc (NasdaqCM: GOVX) announced that Chairman & CEO David Dodd will participate in the Benzinga Global Small Cap Conference on May 13-14, 2021. Dodd will deliver a corporate presentation at 9:50am ET and join a panel discussion titled “Investing Post COVID – Back to the Fundamentals” at 11:50am ET on May 13. The panel will focus on healthcare investing in a post-COVID environment. Investors can also request one-on-one meetings with Dodd after the conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

GeoVax Labs, Inc. (NASDAQ: GOVX) will report its first quarter 2021 financial results on May 6, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET, aimed at discussing financial results and company updates. The call will include a Q&A session. GeoVax is a clinical-stage biotechnology firm specializing in vaccines for infectious diseases and cancer, using a patented MVA-VLP platform. Their current developments include vaccines for COVID-19, HIV, Zika Virus, and various cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

GeoVax Labs (NasdaqCM: GOVX) announced a Notice of Allowance for a patent on methods to generate an immune response to Hepatitis B Virus (HBV), a critical unmet medical need affecting over 250 million people globally. The patent is co-owned with Georgia State University, emphasizing collaboration in combating chronic HBV infections. While the company's main focus remains on COVID-19 vaccines and cancer therapies, the development of an HBV treatment is part of its long-term strategy. This patent adds to GeoVax's growing portfolio of over 70 patents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

GeoVax Labs, Inc. (GOVX, GOVXW) reported its 2020 financial results, showing a net loss of $3.0 million, up from $2.4 million in 2019. Grant revenues increased from $1.2 million to $1.8 million, primarily due to U.S. Department of Defense support for the Lassa Fever vaccine. As of December 31, 2020, cash balances rose significantly to $9.9 million, compared to $283,341 in 2019, supported by a $11.2 million public offering. The company is advancing its COVID-19 vaccine and immuno-oncology programs, with several data announcements expected in the first half of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

GeoVax Labs (NasdaqCM: GOVX) announces participation in the Benzinga Biotech Small Cap Conference on March 24-25, 2021. CEO David Dodd will present an overview of the company’s immunotherapy and vaccine R&D, focusing on its COVID-19 vaccine targeting various SARS-CoV-2 variants. Chief Scientific Officer Mark Newman, PhD, will join a panel on advancements in cancer immunotherapies. Investors can view the presentations by registering for the conference and can request one-on-one meetings with Dodd.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

GeoVax Labs, Inc. (GOVX) has scheduled its 2020 financial results release for March 23, 2021, after market close. A conference call will follow on March 24, 2021, at 8:00 a.m. ET, to discuss these results and corporate updates. The company specializes in human immunotherapies and vaccines targeting infectious diseases and cancer, utilizing its proprietary Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform. Upcoming developments include preventive vaccines for COVID-19, HIV, and other diseases, with potential human clinical trials managed with the National Institutes of Health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary

GeoVax Labs, Inc. (GOVX) is set to present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. The company’s Chairman and CEO, David Dodd, will discuss ongoing research in COVID-19 and cancer immunotherapy. Additionally, Mark Newman, PhD, Chief Scientific Officer, will join a panel on cancer vaccines and immuno-oncology. Investors can register for the conference to view presentations and schedule one-on-one meetings with Dodd.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of GeoVax Labs Warrants (GOVXW)?

The current stock price of GeoVax Labs Warrants (GOVXW) is $0.1245 as of December 20, 2024.

What is GeoVax Labs, Inc. focused on developing?

GeoVax Labs, Inc. is focused on developing human vaccines and immunotherapies for infectious diseases and solid tumor cancers using innovative proprietary platforms.

What recent achievements has GeoVax Labs, Inc. made?

GeoVax Labs, Inc. achieved positive initial safety and immune response findings in a Phase 2 clinical trial for its COVID-19 vaccine.

Which diseases are targeted by GeoVax's vaccine development programs?

GeoVax targets infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), Zika virus, along with developing immunotherapies for various solid tumors.

GeoVax Labs, Inc. Warrants

Nasdaq:GOVXW

GOVXW Rankings

GOVXW Stock Data

5.24M
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SMYRNA